Scholarlink

<p>Cancer proteomics is crucial for understanding tumor biology, yet consistent quantification of clinically relevant proteins across analytical platforms remains challenging. Here, we compared Reverse Phase Protein Array (RPPA) and Liquid Chromatography-Mass Spectrometry (LC-MS) using identical lysate aliquots prepared from matched tumor and adjacent normal tissues from breast and kidney cancer patients. We focused on proteins encoded by genes represented in the Ion AmpliSeq Cancer Hotspot Panel v2 and included representative cellular markers. RPPA was applied to the larger sample set, whereas data-dependent, data-independent, and targeted parallel reaction monitoring LC-MS modes were performed on a smaller subset of lysates. RPPA identified tumor-normal differences for several proteins and cell markers, while LC-MS quantified a smaller overlapping subset in the matched samples analyzed by both platforms. Cross-platform comparison showed that agreement was partial and strongly protein dependent: some targets displayed concordant tumor/normal fold changes, whereas others exhibited weak or even opposite-direction changes. Targeted PRM modestly improved agreement for selected discordant proteins, but substantial discrepancies remained. These data indicate that RPPA and LC-MS are not interchangeable for quantifying all targets in this panel, calling for a rather confirmatory approach: concordant findings increase confidence in selected candidate biomarkers, whereas discordant findings identify targets that require cautious interpretation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparative analysis and correlation of cancer hotspot proteins and cell markers in tumor-normal adjacent breast and kidney samples using RPPA and LC-MS

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月18日

查看全文
  • Krisztina Paal,
  • Noemi Karnok,
  • Csaba Konrad,
  • David Bui,
  • Fanni Bugyi,
  • Lilla Turiák,
  • Christos Chinopoulos

摘要

Cancer proteomics is crucial for understanding tumor biology, yet consistent quantification of clinically relevant proteins across analytical platforms remains challenging. Here, we compared Reverse Phase Protein Array (RPPA) and Liquid Chromatography-Mass Spectrometry (LC-MS) using identical lysate aliquots prepared from matched tumor and adjacent normal tissues from breast and kidney cancer patients. We focused on proteins encoded by genes represented in the Ion AmpliSeq Cancer Hotspot Panel v2 and included representative cellular markers. RPPA was applied to the larger sample set, whereas data-dependent, data-independent, and targeted parallel reaction monitoring LC-MS modes were performed on a smaller subset of lysates. RPPA identified tumor-normal differences for several proteins and cell markers, while LC-MS quantified a smaller overlapping subset in the matched samples analyzed by both platforms. Cross-platform comparison showed that agreement was partial and strongly protein dependent: some targets displayed concordant tumor/normal fold changes, whereas others exhibited weak or even opposite-direction changes. Targeted PRM modestly improved agreement for selected discordant proteins, but substantial discrepancies remained. These data indicate that RPPA and LC-MS are not interchangeable for quantifying all targets in this panel, calling for a rather confirmatory approach: concordant findings increase confidence in selected candidate biomarkers, whereas discordant findings identify targets that require cautious interpretation.